通过多式联络深度学习和可解释的人工智能提升早期帕金森病检测:PPMI数据库的见解
Vincenzo Dentamaro1, Donato Impedovo2, Luca Musti2
1Dipartimento di Informatica, University of Bari Aldo Moro, 70125, Bari, Italy. vincenzo.dentamaro@uniba.it.
Scientific reports
|September 9, 2024
概括
这项研究使用多式模式深度学习来早期检测帕金森病 (PD). 它将成像和临床数据与人工智能结合起来,识别出用于早期诊断和精准医学的关键大脑区域.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 帕金森病 (PD) 是一种常见的神经退行性疾病,影响全球数百万人.
- 早期发现PD对于有效的管理和治疗至关重要.
研究的目的:
- 为了研究多式联机深度学习用于前期帕金森病的检测.
- 整合成像和临床数据,使用一种新的共同学习方法.
- 通过可解释AI (XAI) 技术来提高诊断准确性.
主要方法:
- 使用了帕金森病进展标记计划 (PPMI) 数据集.
- 开发了一个共同的共同学习框架,用于深度神经网络中的多式联络数据融合.
- 使用3D卷积神经网络 (CNN) 与激发网络 (EN) 和视觉变换器 (ViT).
- 应用了XAI方法,如集成梯度和注意力热图,以提高模型的可解释性.
主要成果:
- 配备EN的DenseNet表现出卓越的性能,在包括临床数据时显著提高了准确性.
- XAI分析显示,DenseNet的重点是对前进性PD的关键大脑区域 (右,左前额) 的关注.
- ViT突出了侧腔室,可能与早期PD阶段的认知衰退有关.
结论:
- 拟议的多式联络深度学习框架有效地帮助早期的PD诊断和亚型预测.
- 确定的大脑区域和侧腔室显示为帕金森病的早期生物标志物具有前途.
- 这些发现支持开发用于神经退行性疾病的精准医学的先进诊断工具.
相关概念视频
Parkinson's Disease: Treatment
237
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
237
Parkinson's Disease: Overview
498
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
498


